Johann K Hitzler

33PUBLICATIONS
157CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Molecular targetsRespiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jul 29, 2026
How I Approach Treatment of Relapsed Acute Lymphoblastic Leukemia in Patients With Down Syndrome.

|Apr 20, 2026
IFN-γ drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.

|Apr 07, 2026
DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome-associated myeloid leukemia.

Lonneke Verboon, Sonali P Barwe, Meredith Tavenner

|Oct 22, 2025
Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.

Jason N Berman, Anupam Verma, Shelton Viola

|Jul 17, 2025
Clinical utility of targeted RNA sequencing in cancer molecular diagnostics.

Robert Siddaway, Aida I Glembocki, Anthony Arnoldo

|Jan 01, 2025
An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup.

Mark Gower, Ximing Li, Alicia G Aguilar-Navarro

Pageof 6

Frequent Collaborators

5 joint publications

Reuven Schore

4 joint publications

Sarah Cohen-Gogo

3 joint publications

Adam Shlien

3 joint publications

Mohamed Abdelhaleem